해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 9.27. (금)

 

구분	보고서(영문)
제약/바이오/임상시험 (6건)	Imfinzi Joins Checkpoint Inhibitor Battle in the Perioperative NSCLC Space
	Enhertu Wins FDA Breakthrough Therapy Designation in HER2-Low/Ultralow Breast Cancer
	Keytruda Beaten by Summit’s Bispecific in NSCLC
	As GSK Discontinues HSV Vaccine, Opportunities Remain for Moderna and BioNTech
	FDA Hits Ozempic and Mounjaro Counterfeit Compounders with Warning Letters
	Biosecure Act Passes US House, Lawmakers Allege US Companies Involved in Unethical Chinese Trials
컨퍼런스/ 심포지엄/ 학회/기타  (11건)	ESMO 2024: IMbrave050 Study Results Fade the Hope of Tecentriq + Avastin as First Adjuvant Therapy for HCC
	EASD 2024: GLP-1R Agonists Treatment Improves Glucose Control and Reduces Bodyweight in Type 1 Diabetes Patients
	ESMO 2024: Enhertu to Eclipse the Standard of Care in HER2+ Breast Cancer with Brain Metastases
	ESMO 2024: Anlotinib and Penpulimab, to the Moon and Beyond for Advanced HCC?
	ESMO 2024: Emerging TROP2-Directed ADCs Provide Promise in Recurrent Endometrial and Ovarian Cancers
	ESMO 2024: TIGIT Race Tightens with First Look at GSK & iTeos’s TIGIT in NSCLC
	ESMO 2024: AstraZeneca’s Imfinzi to Change Perioperative Bladder Cancer Setting
	ESMO 2024: Eli Lilly Brings the Competition to Novartis With New Results in mCRPC
	ESMO 2024: Pembrolizumab is KEY to First-Line Treatment of HER2+ mGEJ Adenocarcinoma
	ESMO 2024: Keytruda Keys in on Survival in KEYNOTE-522 High-Risk Early TNBC Patients
	European Society for Medical Oncology (ESMO) 2024 Highlights
질환별 (3건)	World Sepsis Day 2024: Improved Trial Design and Targeted Drugs Remain Unmet Needs
	Uncontrolled Antimicrobial Use to Cause Rise in Deaths Due to Superbugs
	COPD: Seven -Market Drug Forecast and Market Analysis